Cross-protection of recombinant Pasteurella multocida toxin proteins against atrophic rhinitis in mice

Pasteurella multocida (P. multocida) infects the swine respiratory tract and mainly causes atrophic rhinitis (AR). Recently, many commercially inactivated and subunit vaccines have been used as preventive strategies. However, the best antigenic protein portion has not been selected, and the aluminum...

Full description

Saved in:
Bibliographic Details
Published in:Research in veterinary science 2021-07, Vol.137, p.138-143
Main Authors: Wu, Min-Chia, Lo, Yi-Ting, Wu, Hsing-Chieh, Wang, Hsian-Yu, Chu, Chun-Yen
Format: Article
Language:English
Subjects:
Aluminum
Amino acids
Animal vaccines
Antibodies
Antigens
Atrophic rhinitis
Cloning
Cross-protection
Cytokine expression
Cytokines
Cytotoxicity
Genes
Heterologous challenge
Homology
Immune response
Immune system
Immunization
Immunoglobulin G
Interferon
Interleukin 12
Kinases
Pasteurella multocida
Pasteurella multocida toxin
Proteins
Recombinant protein
Respiratory tract
Respiratory tract diseases
Rhinitis
Toxins
Vaccine
Vaccines
Veterinary medicine
Virulence
Virulence factors
γ-Interferon
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pasteurella multocida (P. multocida) infects the swine respiratory tract and mainly causes atrophic rhinitis (AR). Recently, many commercially inactivated and subunit vaccines have been used as preventive strategies. However, the best antigenic protein portion has not been selected, and the aluminum gel was used as the adjuvant, which may not induce full protection. P. multocida toxin (PMT) is the major virulence factor responsible for AR. PMT is a monomeric 146 kDa protein (approximately 1285 amino acids) encoded by the tox A gene. In this study, we expressed different fragments of recombinant PMT proteins, combined them with a water-in-oil-in-water adjuvant, and evaluated mice's immune response. The results indicated that the rPMT-C-immunized group showed significantly higher levels (p 
ISSN:0034-5288
1532-2661
DOI:10.1016/j.rvsc.2021.05.002